Solid Biosciences Inc

0.00 (0.00%)
Products, Regulatory

Solid Biosciences Reports Efficacy And Safety Data From Ongoing IGNITE DMD Clinical Trial And Resumption of Patient Dosing In 2E14 vg/kg Cohort

Published: 03/15/2021 20:55 GMT
Solid Biosciences Inc (SLDB) - Solid Biosciences Reports Efficacy and Safety Data From the Ongoing Ignite Dmd Clinical Trial and Resumption of Patient Dosing in the 2e14 Vg/kg Cohort.
Solid Biosciences Inc - Interim Data From Six Patients Provide Evidence of Potential Benefit of Sgt-001 in Functional Endpoints of Nsaa & 6mwt.
Solid Biosciences Inc - Patient 7, Safely Dosed With Sgt-001, Experienced Transient and Manageable Adverse Events, None of Which Were Serious.